Telix Pharmaceuticals Rallies on Phase 3 Trial Enrollment and FDA Pathway Update

Telix Pharmaceuticals (TLX) stock rose sharply in pre-market trading after the company announced it has completed patient enrollment in its pivotal Phase 3 BiPASS clinical trial. The update, detailed in a Form 6-K filed with the SEC on September 2, 2026, also confirmed that Telix has aligned with the U.S. Food and Drug Administration (FDA) on a path forward for a New Drug Application (NDA).

Key Clinical and Regulatory Progress

The BiPASS study is evaluating the company's commercial PSMA-PET imaging agents, Illuccix and Gozellix, combined with MRI for the detection of prostate cancer before a biopsy. According to Telix, reaching full enrollment is a significant milestone that de-risks a key part of its clinical pipeline.

Crucially, the alignment with the FDA on an NDA pathway for BiPASS is a major development for the company. If ultimately approved, this pathway would support reimbursement for the imaging combination as a distinct new product, potentially expanding patient access significantly beyond its current labeled indications.

Ad

Market Reaction and Analyst Outlook

The market responded positively to the news, with Telix shares gaining 5.2% in pre-open trading to approach $11.42. The advance stood out against a largely flat broader market, where the S&P 500 was little changed, indicating the move was driven by company-specific factors.

Investor confidence was further bolstered by an analyst note from H.C. Wainwright, which reiterated its Buy rating and $20.00 price target on the stock following the announcement. The positive clinical update builds on a strong financial backdrop from the first half of 2026, in which Telix reported a 22% year-over-year revenue increase and a 146% rise in EBITDA.